Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Through the biopsy histopathological examination, imaging examination, and genetic testing, the patient was diagnosed as metastatic PC with BRCA2 mutation.
|
31577767 |
2019 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Comparing 3030 case patients with pancreatic cancer (43.2% female; 95.6% non-Hispanic white; mean age at diagnosis, 65.3 [SD, 10.7] years) with reference controls, significant associations were observed between pancreatic cancer and mutations in CDKN2A (0.3% of cases and 0.02% of controls; odds ratio [OR], 12.33; 95% CI, 5.43-25.61); TP53 (0.2% of cases and 0.02% of controls; OR, 6.70; 95% CI, 2.52-14.95); MLH1 (0.13% of cases and 0.02% of controls; OR, 6.66; 95% CI, 1.94-17.53); BRCA2 (1.9% of cases and 0.3% of controls; OR, 6.20; 95% CI, 4.62-8.17); ATM (2.3% of cases and 0.37% of controls; OR, 5.71; 95% CI, 4.38-7.33); and BRCA1 (0.6% of cases and 0.2% of controls; OR, 2.58; 95% CI, 1.54-4.05).
|
29922827 |
2018 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We confirmed variants in BRCA2 as the most common high-penetrant genetic factor associated with pancreatic cancer and we also identified candidate pancreatic cancer genes.
|
29074453 |
2018 |
Pancreatic carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we determined protein expression of BRCA1 and BRCA2 in 4 digestive system cancers (gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer) by immunohistochemistry on tissue microarrays.
|
29126833 |
2018 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
|
29441441 |
2018 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.
|
30407790 |
2018 |
Pancreatic carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer.
|
28452926 |
2017 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here we present a case of a 63-year-old female patient with a germ line pathogenic BRCA2 mutation (6714 deletion) who developed pancreatic cancer and had an exceptional response to platinum and PARP inhibitor therapy.
|
28291774 |
2017 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Results Thirty-three (3.9%; 95% CI, 3.0% to 5.8%) of 854 patients with pancreatic cancer had a deleterious germline mutation, 31 (3.5%) of which affected known familial pancreatic cancer susceptibility genes: BRCA2 (12 patients), ATM (10 patients), BRCA1 (3 patients), PALB2 (2 patients), MLH1 (2 patients), CDKN2A (1 patient), and TP53 (1 patient).
|
28767289 |
2017 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
BRCA2 mutations in MSH2/MLH1-mutant CRCs included 75 unique mutations not known to occur in breast or pancreatic cancer per COSMIC v73.
|
28591715 |
2017 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the index patient a germline mutation both in the APC and BRCA2 gene was identified while one affected brother showed the BRCA2 mutation only and another brother is supposed to have developed pancreatic cancer due to multiple non-genetic risk factors.
|
27838800 |
2017 |
Pancreatic carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.
|
28078281 |
2016 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The BRCA2 gene is one of the most common genes linked to pancreatic-only cancer families; however, other hereditary cancer syndromes have also been associated with an increased risk for PC.
|
26727920 |
2016 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found that AZD1775 sensitized to gemcitabine-radiation in BRCA2 wild-type but not BRCA2 mutant pancreatic cancer cells.
|
26585231 |
2015 |
Pancreatic carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673.
|
25864590 |
2015 |
Pancreatic carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, the models reveal novel aspects of cancer evolution in carriers of germline BRCA2 mutations, provide new insights into the tumour suppressive role of BRCA2, and establish valuable new preclinical settings for testing approaches to pancreatic cancer therapy; together, these features emphasize the value of GEMMs in cancer research.
|
24268522 |
2014 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
|
24737347 |
2014 |
Pancreatic carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Germ-line mutations in PALB2 lead to a familial predisposition to breast and pancreatic cancer or to Fanconi Anemia subtype N. PALB2 performs its tumor suppressor role, at least in part, by supporting homologous recombination-type double strand break repair (HR-DSBR) through physical interactions with BRCA1, BRCA2, and RAD51.
|
23657012 |
2013 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results demonstrate for the first time that common variants in BRCA2 and MAP2K4 are susceptibility to sporadic pancreatic cancer.
|
23299404 |
2013 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in BRCA1 and BRCA2 are associated with an increased risk of pancreatic cancer.
|
23456555 |
2013 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
One hundred twenty-nine participants with familial pancreatic cancer or with the BRCA2 gene mutation completed a baseline questionnaire prior to their first pancreatic cancer screening and genetic counseling session.
|
21774034 |
2012 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A clinical database review (2000-2009) identified 211 Ashkenazi Jewish (AJ) BC probands who 1) underwent BRCA1/2 mutation analysis by full gene sequencing or directed testing for Ashkenazi founder mutations (BRCA1: 185delAG and 5382insC; BRCA2: 6174delT) and 2) had a FH of PC in a first-, second-, or third-degree relative.
|
21598239 |
2012 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We also reviewed the pedigrees of 8140 pedigrees with a BRCA1 or a BRCA2 mutation for those with a case of pancreatic cancer.
|
23099806 |
2012 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two of the 51 genetically tested patients (4%) were BRCA2 mutation carriers, and both had first-degree relatives with pancreatic cancer.
|
21975290 |
2012 |
Pancreatic carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These consist of high penetrance genes including BRCA2 or PALB2, to more common genetic variation associated with a modest increase risk of pancreatic cancer such as genetic variation at the ABO blood group locus.
|
22162228 |
2012 |